Enjoy complimentary customisation on priority with our Enterprise License!
The hemophilia therapeutics market share is expected to increase by USD 4.47 billion from 2020 to 2025, and the market's growth momentum will accelerate at a CAGR of 6.16%.
This hemophilia therapeutics market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers hemophilia therapeutics market segmentation by type (hemophilia A, hemophilia B, and hemophilia C) and geography (North America, Europe, Asia, and ROW). The hemophilia therapeutics market report also offers information on several market vendors, including Baxter International Inc., Bayer AG, Biogen Inc., CHIESI Farmaceutici SpA, CSL Ltd., F. Hoffmann-La Roche Ltd., Novo Nordisk AS, Pfizer Inc., Sanofi SA, and Takeda Pharmaceutical Co. Ltd. among others.
Download the Free Report Sample to Unlock the Hemophilia Therapeutics Market Size for the Forecast Period and Other Important Statistics
Based on our research output, there has been a neutral impact on the market growth during and post COVID-19 era. The new drug approvals are notably driving the hemophilia therapeutics market growth, although factors such as cost-intensive and complex treatment may impede market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the hemophilia therapeutics industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.
Key Hemophilia Therapeutics Market Driver
In the past years, bleeding episodes in patients with coagulation disorders such as hemophilia were treated with replacement therapy, whole blood and fresh frozen plasma, and specific factor concentrate as a replacement. Despite the availability of safe and effective replacement therapy, patients with hemophilia A and hemophilia B experience a high burden of treatment and breakthrough bleeding. Therefore, the development and approval of new therapeutics with high efficacy and the ability to overcome the above-mentioned challenges have become the priority for researchers. Several players in the market are focused on identifying novel strategies to treat hemophilia. Owing to this, the market has been witnessing the development and approval of therapeutics, which will drive market growth during the forecast period.
Key Hemophilia Therapeutics Market Trend
Currently, most of the hemophilia therapeutics available in the market are short-acting, i.e., used only when the patient suffers from bleeding. Many hemophilia therapeutics also exhibit immunogenic reactions, which result in a reduced therapeutic effect of these products. In order to mitigate these issues, technologies such as recombinant DNA, protein fusion, and PEGylation technologies are used for the production of new therapies with a longer lifespan and fewer immunogenic reactions. For instance, Biogen offers rFVIIIFc, a recombinant next-generation therapeutic product for hemophilia A therapy. It is the firm's leading product and is a truncated version of factor VIII, fused to the Fc domain of an antibody, which extends the half-life of the product in the bloodstream. This recombinant product is developed using Biogen's protein fusion technology. Thus, increased use of technologies for the development of innovative products is expected to drive the hemophilia therapeutics market during the forecast period.
Key Hemophilia Therapeutics Market Challenge
The treatment for hemophilia can turn out to be very complex if proper guidelines are not followed during the preparation of therapeutics and also during consumption. Current treatments pose certain limitations, such as the risk of infection, treatment resistance, poor compliance, and adverse effects. The introduction of novel therapeutics and their successful scale-up have resulted in the reduction of morbidity and mortality associated with hemophilia. These therapeutics have proven effective and have been well-tolerated in the past years to become the standard in hemophilia-related healthcare. However, these therapeutics are expensive, which becomes a financial burden for individuals living with blood disorders and receiving therapies. Therefore, the high treatment cost may adversely affect patient adherence to treatment and become a challenge for market growth during the forecast period.
This hemophilia therapeutics market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2021-2025.
The growth in the global healthcare market will be driven by factors such as increasing life expectancy, improving access to better healthcare in emerging economies, and increasing cases of chronic conditions. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the hemophilia therapeutics market during the forecast period.
The report analyzes the market's competitive landscape and offers information on several market vendors, including:
This statistical study of the hemophilia therapeutics market encompasses successful business strategies deployed by the key vendors. The hemophilia therapeutics market is fragmented and the vendors are deploying growth strategies such as strategic alliances to compete in the market.
To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.
The hemophilia therapeutics market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.
Our report provides extensive information on the value chain analysis for the hemophilia therapeutics market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chains is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.
The value chain of the healthcare market includes the following core components:
The report has further elucidated on other innovative approaches being followed by vendors to ensure a sustainable market presence.
Executive Summary
Market Landscape
Market Sizing
Five Forces Analysis
Market Segmentation by Type
Customer landscape
Geographic Landscape
Vendor Landscape
Vendor Analysis
Appendix
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.
Get the report (PDF) sent to your email within minutes.